Status
Conditions
About
A need exists for non-invasive testing to aid in clinical decision-making for Computerized Tomography (CT) scan detected lung nodules of indeterminate etiology. The investigators hypothesize that biomarkers detectable in blood, sputum or urine may be useful for guiding clinical decisions in the setting of CT detected lung nodules to determine which nodules are malignant and which are benign. The investigators also hypothesize that these biomarkers will decrease in concentration to the normal range after successful surgical treatment of malignant lung nodules.
Full description
The Biomarkers for Diagnosis of Lung Nodules Study is a prospective study of a cohort of 500 individuals with lung nodules of indeterminate etiology that are identified by CT scans. Either biopsy or repeat CT scans must be clinically indicated to determine the etiology of the nodule. Patients will be asked to allow investigators access to CT scan images and spirometry data, and provide blood, sputum, urine, and exhaled breath samples over the course of the study. Patients will also be asked to allow investigators to access pathology records if a biopsy or surgical excision of the nodule is clinically indicated.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adult 18-85 years of age
Patients referred to pulmonologists, oncologists, or thoracic surgeons for the evaluation of peripheral lung nodules found on CT scan.
Repeat CT scans, biopsy or surgical excision are clinically indicated to determine the etiology of the nodule.
One or more lung nodules must be between 8 mm and 30 mm in the greatest diameter.
Patients must be fully informed of the investigational nature of the procedure and sign an informed consent.
Exclusion criteria
550 participants in 1 patient group
Loading...
Central trial contact
Brandi K Kubala; York E Miller, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal